Video content above is prompted by the following:
- Please discuss the unique mechanism of action of B7-H3 and its treatment potential as a subsequent therapy for SCLC, which has progressed after platinum-based chemotherapy.
- Is individual B7-H3 analysis currently available at your institution?
- Please share your impressions of the efficacy outcomes reported in IDeate-Lung02: 52.4% overall response rate, a 5.9-month median duration of response, and a 12.2-month OS.
- How clinically meaningful do you consider a 12-month OS in this study population after a median of 2 prior lines of therapy?
- In terms of simplicity, treatment compliance, and quality of life, how does the dosing schedule of ifinatamab deruxtecan compare with those of topotecan and lurbinectedin?
- In your opinion, what treatment synergies might you expect from a
combination of MK-6070, the tri-specific T-cell engager, and ifinatamab
deruxtecan?- At this stage in early clinical development, which patient and/or disease factors might persuade you to consider dual T-cell engager therapy?
- Given the currently available data on ifinatamab deruxtecan, please evaluate its potential in combination with atezolizumab with or without platinum-based chemotherapy as first-line induction or maintenance therapy in ES-SCLC.
- What would you consider to be statistically significant end points with dual or triple therapy to warrant clinical application in this patient population?